Sarcopenia in type 2 Diabetes mellitus among Asian populations: prevalence and risk factors based on AWGS- 2019: a systematic review and meta-analysis.

IF 2.8 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
M Yogesh, Monika Patel, Rohankumar Gandhi, Abhishek Patel, Khushal Naranbhai Kidecha
{"title":"Sarcopenia in type 2 Diabetes mellitus among Asian populations: prevalence and risk factors based on AWGS- 2019: a systematic review and meta-analysis.","authors":"M Yogesh, Monika Patel, Rohankumar Gandhi, Abhishek Patel, Khushal Naranbhai Kidecha","doi":"10.1186/s12902-025-01935-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia is increasingly recognized as a significant complication in type 2 diabetes mellitus (T2DM), yet its prevalence and risk factors in Asian populations remain incompletely understood using the updated Asian Working Group for Sarcopenia (AWGS) 2019 criteria. The present review aimed to evaluate the prevalence of sarcopenia among Asian T2DM patients and identify associated risk factors using AWGS-2019 criteria through systematic review and meta-analysis.</p><p><strong>Methods: </strong>A comprehensive systematic review of PubMed, SCOPUS, Crossref, Google Scholar, Semantic Scholar, and OpenAlex followed PRISMA guidelines to identify observational studies assessing the magnitude of sarcopenia in type-2 Diabetes mellitus. Random-effect models were used to estimate pooled prevalence and odds ratios (OR) for associated factors. Heterogeneity was quantified using I<sup>2</sup> statistics and Cochran's Q test, where I<sup>2</sup> values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. Subgroup analyses and meta-regression explored heterogeneity sources across all studies. The quality of the studies was assessed by the Joanna Briggs Institute (JBI) criteria. Publication bias was assessed by funnel plot and Egger's test.</p><p><strong>Findings: </strong>Thirty nine studies, including approximately 19,902 participants, were analyzed. The pooled prevalence of confirmed sarcopenia was 23% (95% CI: 18%-27%, p < 0.001) among Asian T2DM patients, with notably higher rates of possible sarcopenia at 61% (95% CI: 28%-86%, p < 0.001) and lower rates of severe sarcopenia at 12.1% (95% CI: 8.4%-16.7%, p < 0.001). Regional variations showed a higher prevalence in Southeast Asia (37.46%) compared to Western Pacific (21.95%). Meta-analysis revealed significant risk factors including older age (OR: 1.13, 95% CI: 1.11-1.16, p < 0.0001), male gender (OR: 2.37, 95% CI: 1.33-4.21, p = 0.0033), hypertension (OR: 3.65, 95% CI: 1.06-12.65, p = 0.0409), diabetes duration (OR: 1.35, 95% CI: 1.05-2.13, p = 0.02), and reduced physical activity (OR: 2.54, 95% CI: 1.92-3.36, p < 0.0001). Higher BMI (OR: 0.63, 95% CI: 0.53-0.75, p < 0.0001) and better vitamin D levels (OR: 0.91, 95% CI: 0.87-0.95, p < 0.001) demonstrated protective effects. Recent studies (2023-2024) showed a higher prevalence than pre-2022 studies (27.85% vs 18.42%, p = 0.0440). DXA-based measurements yielded higher prevalence estimates than BIA-based assessments (29.86% vs 19.52%, p = 0.7121).</p><p><strong>Interpretation: </strong>Sarcopenia affects nearly one-quarter of Asian T2DM patients, with significant regional variations. Age, male gender, hypertension, and physical inactivity were key risk factors, while maintaining a healthy BMI and good nutrition appeared protective. These findings emphasize the importance of regular screening and early intervention strategies, particularly for high-risk patients.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"101"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004733/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Endocrine Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12902-025-01935-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sarcopenia is increasingly recognized as a significant complication in type 2 diabetes mellitus (T2DM), yet its prevalence and risk factors in Asian populations remain incompletely understood using the updated Asian Working Group for Sarcopenia (AWGS) 2019 criteria. The present review aimed to evaluate the prevalence of sarcopenia among Asian T2DM patients and identify associated risk factors using AWGS-2019 criteria through systematic review and meta-analysis.

Methods: A comprehensive systematic review of PubMed, SCOPUS, Crossref, Google Scholar, Semantic Scholar, and OpenAlex followed PRISMA guidelines to identify observational studies assessing the magnitude of sarcopenia in type-2 Diabetes mellitus. Random-effect models were used to estimate pooled prevalence and odds ratios (OR) for associated factors. Heterogeneity was quantified using I2 statistics and Cochran's Q test, where I2 values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. Subgroup analyses and meta-regression explored heterogeneity sources across all studies. The quality of the studies was assessed by the Joanna Briggs Institute (JBI) criteria. Publication bias was assessed by funnel plot and Egger's test.

Findings: Thirty nine studies, including approximately 19,902 participants, were analyzed. The pooled prevalence of confirmed sarcopenia was 23% (95% CI: 18%-27%, p < 0.001) among Asian T2DM patients, with notably higher rates of possible sarcopenia at 61% (95% CI: 28%-86%, p < 0.001) and lower rates of severe sarcopenia at 12.1% (95% CI: 8.4%-16.7%, p < 0.001). Regional variations showed a higher prevalence in Southeast Asia (37.46%) compared to Western Pacific (21.95%). Meta-analysis revealed significant risk factors including older age (OR: 1.13, 95% CI: 1.11-1.16, p < 0.0001), male gender (OR: 2.37, 95% CI: 1.33-4.21, p = 0.0033), hypertension (OR: 3.65, 95% CI: 1.06-12.65, p = 0.0409), diabetes duration (OR: 1.35, 95% CI: 1.05-2.13, p = 0.02), and reduced physical activity (OR: 2.54, 95% CI: 1.92-3.36, p < 0.0001). Higher BMI (OR: 0.63, 95% CI: 0.53-0.75, p < 0.0001) and better vitamin D levels (OR: 0.91, 95% CI: 0.87-0.95, p < 0.001) demonstrated protective effects. Recent studies (2023-2024) showed a higher prevalence than pre-2022 studies (27.85% vs 18.42%, p = 0.0440). DXA-based measurements yielded higher prevalence estimates than BIA-based assessments (29.86% vs 19.52%, p = 0.7121).

Interpretation: Sarcopenia affects nearly one-quarter of Asian T2DM patients, with significant regional variations. Age, male gender, hypertension, and physical inactivity were key risk factors, while maintaining a healthy BMI and good nutrition appeared protective. These findings emphasize the importance of regular screening and early intervention strategies, particularly for high-risk patients.

亚洲人群中2型糖尿病肌肉减少症:基于AWGS- 2019的患病率和危险因素:系统回顾和荟萃分析
背景:肌少症越来越被认为是2型糖尿病(T2DM)的一个重要并发症,但使用最新的亚洲肌少症工作组(AWGS) 2019标准,其在亚洲人群中的患病率和危险因素仍未完全了解。本综述旨在通过系统评价和荟萃分析,评估亚洲2型糖尿病患者肌肉减少症的患病率,并使用AWGS-2019标准确定相关危险因素。方法:根据PRISMA指南,对PubMed、SCOPUS、Crossref、谷歌Scholar、Semantic Scholar和OpenAlex进行全面的系统评价,以确定评估2型糖尿病肌肉减少程度的观察性研究。随机效应模型用于估计合并患病率和相关因素的优势比(OR)。异质性采用I2统计量和Cochran’s Q检验进行量化,其中I2值为25%、50%和75%分别表示低、中、高异质性。亚组分析和元回归探讨了所有研究的异质性来源。研究的质量由乔安娜布里格斯研究所(JBI)的标准进行评估。采用漏斗图和Egger检验评价发表偏倚。研究结果:对39项研究,包括大约19,902名参与者进行了分析。证实的肌肉减少症的总患病率为23% (95% CI: 18%-27%, p)解释:肌肉减少症影响近四分之一的亚洲2型糖尿病患者,具有显著的地区差异。年龄、男性、高血压和缺乏运动是关键的危险因素,而保持健康的BMI和良好的营养则具有保护作用。这些发现强调了定期筛查和早期干预策略的重要性,特别是对高危患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Endocrine Disorders
BMC Endocrine Disorders ENDOCRINOLOGY & METABOLISM-
CiteScore
4.40
自引率
0.00%
发文量
280
审稿时长
>12 weeks
期刊介绍: BMC Endocrine Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of endocrine disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信